Connection
William Robinson to Melanoma
This is a "connection" page, showing publications William Robinson has written about Melanoma.
|
|
Connection Strength |
|
 |
|
 |
|
7.218 |
|
|
|
-
Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA. ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther. 2018 01; 17(1):222-231.
Score: 0.347
-
Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res. 2017 06; 27(3):189-199.
Score: 0.337
-
Ross E, Robinson SE, Amato C, McMillan C, Westcott J, Wolf T, Robinson WA. Therapeutic monoclonal antibodies in human breast milk: a case study. Melanoma Res. 2014 Apr; 24(2):177-80.
Score: 0.271
-
Barr J, Amato CM, Robinson SE, Kounalakis N, Robinson WA. The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma. Melanoma Res. 2012 Feb; 22(1):92-5.
Score: 0.233
-
Lyle PL, Amato CM, Fitzpatrick JE, Robinson WA. Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma. Am J Surg Pathol. 2008 Jun; 32(6):858-66.
Score: 0.181
-
Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 2008 Mar 01; 68(5):1362-8.
Score: 0.178
-
High WA, Robinson WA. Genetic mutations involved in melanoma: a summary of our current understanding. Adv Dermatol. 2007; 23:61-79.
Score: 0.164
-
Pearlman NW, McCarter MD, Frank M, Hurtubis C, Merkow RP, Franklin WA, Gonzalez R, Lewis K, Roaten JB, Robinson WA. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 2006 Dec; 192(6):878-81.
Score: 0.163
-
Yee EJ, Thielen ON, Truong R, Gilbert D, Michel K, Couts KL, Robinson WA, McCarter MD. Metastatic Melanoma to the Small Bowel and Colon: A Systematic Review of the Global Experience and Institutional Cohort Analysis Detailing a Rare Clinical Entity. J Surg Oncol. 2025 Mar; 131(4):671-684.
Score: 0.141
-
Turner JA, Van Gulick RJ, Robinson WA, Mughal T, Tobin RP, MacBeth ML, Holman B, Classon A, Bagby SM, Yacob BW, Hartman SJ, Silverman I, Vorwald VM, Gorden N, Gonzalez R, Gay LM, Ali SM, Benson A, Miller VA, Ross JS, Pitts TM, Rioth MJ, Lewis KD, Medina T, McCarter MD, Gonzalez R, Couts KL. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. Int J Cancer. 2024 Nov 15; 155(10):1792-1807.
Score: 0.138
-
Mukherjee N, Katsnelson E, Brunetti TM, Michel K, Couts KL, Lambert KA, Robinson WA, McCarter MD, Norris DA, Tobin RP, Shellman YG. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. Cell Death Dis. 2024 03 08; 15(3):198.
Score: 0.135
-
Robinson WA, Miller TL, Harrold EA, Bemis LT, Brady BM, Nelson RP. The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines. Melanoma Res. 2003 Jun; 13(3):231-8.
Score: 0.128
-
Vaddi PK, Osborne DG, Nicklawsky A, Williams NK, Menon DR, Smith D, Mayer J, Reid A, Domenico J, Nguyen GH, Robinson WA, Ziman M, Gao D, Zhai Z, Fujita M. CTLA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients. Front Immunol. 2023; 14:1173035.
Score: 0.127
-
Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
Score: 0.126
-
Newell F, Johansson PA, Wilmott JS, Nones K, Lakis V, Pritchard AL, Lo SN, Rawson RV, Kazakoff SH, Colebatch AJ, Koufariotis LT, Ferguson PM, Wood S, Leonard C, Law MH, Brooks KM, Broit N, Palmer JM, Couts KL, Vergara IA, Long GV, Barbour AP, Nieweg OE, Shivalingam B, Robinson WA, Stretch JR, Spillane AJ, Saw RPM, Shannon KF, Thompson JF, Mann GJ, Pearson JV, Scolyer RA, Waddell N, Hayward NK. Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. Cancer Discov. 2022 12 02; 12(12):2856-2879.
Score: 0.124
-
Akturk HK, Couts KL, Baschal EE, Karakus KE, Van Gulick RJ, Turner JA, Pyle L, Robinson WA, Michels AW. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. JAMA Netw Open. 2022 12 01; 5(12):e2246400.
Score: 0.124
-
Gibbs P, Brady BM, Robinson WA. The genes and genetics of malignant melanoma. J Cutan Med Surg. 2002 May-Jun; 6(3):229-35.
Score: 0.118
-
Mukherjee N, Dart CR, Amato CM, Honig-Frand A, Lambert JR, Lambert KA, Robinson WA, Tobin RP, McCarter MD, Couts KL, Fujita M, Norris DA, Shellman YG. Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. J Invest Dermatol. 2022 07; 142(7):1912-1922.e7.
Score: 0.116
-
Torphy RJ, Friedman C, Ho F, Leonard LD, Thieu D, Lewis KD, Medina TM, Robinson WA, Gonzalez RC, Stewart CL, Kounalakis N, McCarter MD, Gleisner A. Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection. Ann Surg Oncol. 2022 Feb; 29(2):806-815.
Score: 0.114
-
Gibbs P, Brady BM, Gonzalez R, Robinson WA. Nevi and melanoma: lessons from Turner's syndrome. Dermatology. 2001; 202(1):1-3.
Score: 0.108
-
Holman BN, Van Gulick RJ, Amato CM, MacBeth ML, Davies KD, Aisner DL, Robinson WA, Couts KL. Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. Melanoma Res. 2020 12; 30(6):562-573.
Score: 0.108
-
Newell F, Wilmott JS, Johansson PA, Nones K, Addala V, Mukhopadhyay P, Broit N, Amato CM, Van Gulick R, Kazakoff SH, Patch AM, Koufariotis LT, Lakis V, Leonard C, Wood S, Holmes O, Xu Q, Lewis K, Medina T, Gonzalez R, Saw RPM, Spillane AJ, Stretch JR, Rawson RV, Ferguson PM, Dodds TJ, Thompson JF, Long GV, Levesque MP, Robinson WA, Pearson JV, Mann GJ, Scolyer RA, Waddell N, Hayward NK. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020 10 16; 11(1):5259.
Score: 0.107
-
Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 06 08; 11(6):443.
Score: 0.104
-
Friedman C, Lyon M, Torphy RJ, Thieu D, Hosokawa P, Gonzalez R, Lewis KD, Medina TM, Rioth MJ, Robinson WA, Kounalakis N, McCarter MD, Gleisner AL. A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. J Surg Oncol. 2019 Dec; 120(7):1276-1283.
Score: 0.099
-
Yeh I, Jorgenson E, Shen L, Xu M, North JP, Shain AH, Reuss D, Wu H, Robinson WA, Olshen A, von Deimling A, Kwok PY, Bastian BC, Asgari MM. Targeted Genomic Profiling of Acral Melanoma. J Natl Cancer Inst. 2019 10 01; 111(10):1068-1077.
Score: 0.099
-
Mackin AG, Pecen PE, Dinsmore AL, Patnaik JL, Gonzalez R, Robinson WA, Palestine AG. Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
Score: 0.099
-
Osborne DG, Domenico J, Luo Y, Reid AL, Amato C, Zhai Z, Gao D, Ziman M, Dinarello CA, Robinson WA, Fujita M. Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. Mol Carcinog. 2019 09; 58(9):1670-1679.
Score: 0.097
-
Gibbs P, Cebon JS, Calafiore P, Robinson WA. Cardiac metastases from malignant melanoma. Cancer. 1999 Jan 01; 85(1):78-84.
Score: 0.094
-
Sinik L, Minson KA, Tentler JJ, Carrico J, Bagby SM, Robinson WA, Kami R, Burstyn-Cohen T, Eckhardt SG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. Mol Cancer Ther. 2019 02; 18(2):278-288.
Score: 0.094
-
Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, Robinson WA, Messersmith WA, Fujita M. CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. Cancer Res. 2018 12 01; 78(23):6561-6574.
Score: 0.093
-
Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL. BRAF fusions identified in melanomas have variable treatment responses and phenotypes. Oncogene. 2019 02; 38(8):1296-1308.
Score: 0.092
-
Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, Amato CM, Couts KL, Bemis JGT, Turner JA, Norris DA, Shellman YG. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis. 2018 09 05; 9(9):907.
Score: 0.092
-
Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, Lewis KD, McCarter MD. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018 Oct; 63:282-291.
Score: 0.092
-
Gibbs P, Chen Q, Robinson WA. Effects of oncostatin M and tamoxifen on human melanoma cells. Melanoma Res. 1998 Jun; 8(3):221-6.
Score: 0.090
-
Korch C, Hall EM, Dirks WG, Ewing M, Faries M, Varella-Garcia M, Robinson S, Storts D, Turner JA, Wang Y, Burnett EC, Healy L, Kniss D, Neve RM, Nims RW, Reid YA, Robinson WA, Capes-Davis A. Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. Int J Cancer. 2018 02 01; 142(3):561-572.
Score: 0.086
-
Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017 Jul 18; 8(29):46801-46817.
Score: 0.085
-
Mukherjee N, Almeida A, Partyka KA, Lu Y, Schwan JV, Lambert K, Rogers M, Robinson WA, Robinson SE, Applegate AJ, Amato CM, Luo Y, Fujita M, Norris DA, Shellman YG. Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. Oncotarget. 2016 Dec 20; 7(51):84594-84607.
Score: 0.082
-
Robinson WA, Elefanty AG, Hersey P. Expression of the tumour suppressor genes p15 and p16 in malignant melanoma. Melanoma Res. 1996 Aug; 6(4):285-9.
Score: 0.080
-
Hintzsche J, Kim J, Yadav V, Amato C, Robinson SE, Seelenfreund E, Shellman Y, Wisell J, Applegate A, McCarter M, Box N, Tentler J, De S, Robinson WA, Tan AC. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples. J Am Med Inform Assoc. 2016 07; 23(4):721-30.
Score: 0.078
-
Dreiling L, Hoffman S, Robinson WA. Melanoma: epidemiology, pathogenesis, and new modes of treatment. Adv Intern Med. 1996; 41:553-604.
Score: 0.076
-
Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol. 2015 Mar; 135(3):842-850.
Score: 0.070
-
Kane MA, Johnson A, Nash AE, Boose D, Mathai G, Balmer C, Yohn JJ, Robinson WA. Serum melatonin levels in melanoma patients after repeated oral administration. Melanoma Res. 1994 Feb; 4(1):59-65.
Score: 0.067
-
Prasad KN, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson WA. Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer. 1994; 22(3):233-45.
Score: 0.067
-
Morse HG, Moore GE, Ortiz LM, Gonzalez R, Robinson WA. Malignant melanoma: from subcutaneous nodule to brain metastasis. Cancer Genet Cytogenet. 1994 Jan; 72(1):16-23.
Score: 0.067
-
Johnson A, Mathai G, Robinson WA. Malignant melanoma of the perineum. J Surg Oncol. 1993 Nov; 54(3):185-9.
Score: 0.066
-
Jones TS, Jones EL, Gao D, Pearlman NW, Robinson WA, McCarter M. Management of external ear melanoma: the same or something different? Am J Surg. 2013 Sep; 206(3):307-13.
Score: 0.064
-
Jones EL, Jones TS, Pearlman NW, Gao D, Stovall R, Gajdos C, Kounalakis N, Gonzalez R, Lewis KD, Robinson WA, McCarter MD. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013 May; 148(5):456-61.
Score: 0.064
-
Deng H, Liu J, Deng Y, Han G, Shellman YG, Robinson SE, Tentler JJ, Robinson WA, Norris DA, Wang XJ, Zhang Q. CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1. J Invest Dermatol. 2013 May; 133(5):1294-301.
Score: 0.062
-
Sanchez JA, Robinson WA. Malignant melanoma. Annu Rev Med. 1993; 44:335-42.
Score: 0.062
-
Morse HG, Gonzalez R, Moore GE, Robinson WA. Preferential chromosome 11q and/or 17q aberrations in short-term cultures of metastatic melanoma in resections from human brain. Cancer Genet Cytogenet. 1992 Dec; 64(2):118-26.
Score: 0.062
-
Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012 Oct; 30(10):2100-13.
Score: 0.061
-
Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, Ahn NG, Fujita M. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-2450.
Score: 0.060
-
Arora R, Robinson WA. Breast metastases from malignant melanoma. J Surg Oncol. 1992 May; 50(1):27-9.
Score: 0.059
-
Gonzalez R, Salem P, Bunn PA, Zukiwski AA, Lamb R, Benjamin RS, Spitler L, Wedel N, Robinson WA. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial. Mol Biother. 1991 Dec; 3(4):192-6.
Score: 0.058
-
Gonzalez R, Sanchez A, Ferguson JA, Balmer C, Daniel C, Cohn A, Robinson WA. Melatonin therapy of advanced human malignant melanoma. Melanoma Res. 1991 Nov-Dec; 1(4):237-43.
Score: 0.057
-
Luo Y, Robinson S, Fujita J, Siconolfi L, Magidson J, Edwards CK, Wassmann K, Storm K, Norris DA, Bankaitis-Davis D, Robinson WA, Fujita M. Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma. PLoS One. 2011; 6(6):e20971.
Score: 0.056
-
Mughal TI, Thomas MR, Robinson WA. Role of recombinant alpha-interferon in the treatment of advanced cutaneous malignant melanoma. Oncology. 1991; 48(5):365-8.
Score: 0.054
-
Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock PM, Lozano G, Robinson WA, Roop DR, Box NF. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res. 2010 Dec; 23(6):781-94.
Score: 0.054
-
Robinson WA. Malignant melanoma as a model for cancer education and prevention. 1989 Harvey lecture American Association for Cancer Education. J Cancer Educ. 1990; 5(2):85-9.
Score: 0.050
-
Juhl AL, Byers TE, Robinson WA, Morelli JG, Crane LA. The anatomic distribution of melanoma and relationships with childhood nevus distribution in Colorado. Melanoma Res. 2009 Aug; 19(4):252-9.
Score: 0.049
-
Frontiera M, Murray JL, Lamki L, Thomas J, Satterlee W, Schmelter R, Rosenblum MG, Khazaeli MB, Unger MW, Robinson WA, et al. Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma. Clin Nucl Med. 1989 May; 14(5):357-66.
Score: 0.048
-
Rifkin RM, Thomas MR, Mughal TI, Kaur JS, Krebs LU, Robinson WA. Malignant melanoma--profile of an epidemic. West J Med. 1988 Jul; 149(1):43-6.
Score: 0.045
-
Baumgartner JM, Gonzalez R, Lewis KD, Robinson WA, Richter DA, Palmer BE, Wilson CC, McCarter MD. Increased survival from stage IV melanoma associated with fewer regulatory T Cells. J Surg Res. 2009 Jun 01; 154(1):13-20.
Score: 0.045
-
Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs. 2008 Feb; 26(1):89-94.
Score: 0.043
-
Zartman GM, Thomas MR, Robinson WA. Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol. 1987 Jul; 35(3):163-4.
Score: 0.042
-
Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology. 1986 Sep; 172(3-5):275-82.
Score: 0.040
-
Ravdel L, Robinson WA, Lewis K, Gonzalez R. Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol. 2006 Aug 01; 94(2):101-4.
Score: 0.040
-
Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
Score: 0.040
-
Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Kuo C, Wang HJ, Milford R, Morton DL, Hoon DS. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res. 2006 Feb 15; 12(4):1137-43.
Score: 0.039
-
Schmelter RF, Friefeld GD, Thomas J, Robinson WA. Diagnosis of malignant melanoma with radiolabeled monoclonal antibodies: current status. Drug Intell Clin Pharm. 1986 Feb; 20(2):125-33.
Score: 0.038
-
Lewis KD, Thompson JA, Weber JS, Robinson WA, O'Day S, Lutzky J, Legha SS, Floret S, Ruvuna F, Gonzalez R. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan; 24(1):89-94.
Score: 0.038
-
Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang HJ, Elashoff RM, Takeuchi H, Umetani N, Hoon DS. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005 Nov 01; 23(31):8057-64.
Score: 0.038
-
Lewis KD, Gonzalez R, Robinson WA, Fitzpatrick JE, McCarter MD, Braden C. A young woman with melanoma diagnosed during pregnancy. Oncology (Williston Park). 2004 Jun; 18(7):794-9.
Score: 0.034
-
Gibbs P, Robinson WA, Pearlman N, Raben D, Walsh P, Gonzalez R. Management of primary cutaneous melanoma of the head and neck: The University of Colorado experience and a review of the literature. J Surg Oncol. 2001 Jul; 77(3):179-85; discussion 186-7.
Score: 0.028
-
Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998 Jul; 187(1):69-77; discussion 77-9.
Score: 0.023
-
Wallack MK, Sivanandham M, Ditaranto K, Shaw P, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Rosen L, Bartolucci AA. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg. 1997 Aug; 226(2):198-206.
Score: 0.021
-
Pearlman NW, Robinson WA, Dreiling LK, McIntyre RC, Gonzales R. Modified ilioinguinal node dissection for metastatic melanoma. Am J Surg. 1995 Dec; 170(6):647-9; discussion 649-50.
Score: 0.019
-
Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K, Clendeninn NJ. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma. Am J Clin Oncol. 1995 Dec; 18(6):488-90.
Score: 0.019
-
Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty LE, Richards JM, Bartolucci AA, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer. 1995 Jan 01; 75(1):34-42.
Score: 0.018
-
Pearlman NW, Takach TJ, Robinson WA, Ferguson J, Cohen AL. A case-control study of late recurrence of malignant melanoma. Am J Surg. 1992 Nov; 164(5):458-60; discussion 460-1.
Score: 0.015
-
Feun LG, Gonzalez R, Savaraj N, Hanlon J, Collier M, Robinson WA, Clendeninn NJ. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. J Clin Oncol. 1991 Mar; 9(3):464-7.
Score: 0.014
-
Brega K, Robinson WA, Winston K, Wittenberg W. Surgical treatment of brain metastases in malignant melanoma. Cancer. 1990 Nov 15; 66(10):2105-10.
Score: 0.013
-
Kirkwood JM, Ernstoff MS, Giuliano A, Gams R, Robinson WA, Costanzi J, Pouillart P, Speyer J, Grimm M, Spiegel R. Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst. 1990 Jun 20; 82(12):1062-3.
Score: 0.013
-
Mughal TI, Robinson WA, Thomas MR, Spiegel R. Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma. J Cancer Res Clin Oncol. 1988; 114(1):108-9.
Score: 0.011
-
Thomas MR, Robinson WA, Mughal TI, Morton N, Glode LM. Recovery of blood and bone marrow stem cells following intense chemotherapy and autologous bone marrow transplantation. Oncology. 1986; 43(5):273-7.
Score: 0.010
-
Mughal TI, Robinson WA, Thomas MR, Glode LM. Malignant melanoma and BCNU. Clin Oncol. 1984 Jun; 10(2):185.
Score: 0.009
-
Dantas ME, Brown JP, Thomas MR, Robinson WA, Glode LM. Detection of melanoma cells in bone marrow using monoclonal antibodies. A comparison of fluorescence activated cell sorting (FACS) and conventional immunofluorescence (IF). Cancer. 1983 Sep 15; 52(6):949-53.
Score: 0.008
-
Thomas PJ, Kaur JS, Aitcheson CT, Robinson WA, Tan EM. Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma. Cancer Res. 1983 Mar; 43(3):1372-80.
Score: 0.008
-
Thomas MR, Robinson WA, Glode LM, Dantas ME, Koeppler H, Morton N, Sutherland J. Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study. Am J Clin Oncol. 1982 Dec; 5(6):611-22.
Score: 0.008
-
Hartmann DW, Robinson WA, Morton NJ, Mangalik A, Glode LM. High-dose nitrogen mustard (HN2) with autologous nonfrozen bone marrow transplantation in advanced malignant melanoma. A phase I trial. Blut. 1981 Apr; 42(4):209-20.
Score: 0.007
-
Hartmann DW, Robinson WA, Mangalik A, Glode LM, Triebel F. Unanticipated side effects from treatment with high-dose mechlorethamine in patients with malignant melanoma. Cancer Treat Rep. 1981 Mar-Apr; 65(3-4):327-8.
Score: 0.007
-
Pacheco TR, Maxwell F, Vasiloudes PE, Robinson WA, Norris DA, Maxwell IH. Positive tetracycline control of expression of p15INK4B from an Epstein-Barr autonomous plasmid in a human melanoma cell line. Gene. 2000 Jan 25; 242(1-2):249-56.
Score: 0.006
-
Gibson EL, Herbert V, Robinson WA. Granulocyte colony stimulating activity and vitamin B12 binding proteins in human urine. Br J Haematol. 1974 Oct; 28(2):191-7.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|